Highlights from the 2008 Annual Meeting of the American Society of Clinical Oncology
Roy S. Herbst, MD, PhD
Chief, Section of Thoracic Medical Oncology
Professor of Medicine and Cancer Biology
Department of Thoracic/Head & Neck Medical Oncology
Co-Director, Phase I Clinical Trials Working Group
The University of Texas M. D. Anderson Cancer Center
95 Combining Chemotherapy With Other
Drugs to Treat Metastatic Non-Small Cell
Chemotherapy Combined With Cetuximab (p 95)
Adding the targeted treatment cetuximab (Erbitux) to
chemotherapy as first-line treatment of metastatic NSCLC may
help patients survive longer.
Chemotherapy Combined With CP-751,871 (p 97)
For people with metastatic lung cancer, adding a protein known
as CP-751,871 to chemotherapy with paclitaxel (Taxol and
others) and carboplatin (Paraplatin and others) appears to be
effective in shrinking tumors.
Pemetrexed as Maintenance Chemotherapy
Maintenance chemotherapy with pemetrexed (Alimta) appears
to delay the growth of cancer in people who have metastatic
Sorafenib for Chemotherapy-Resistant Lung
Cancer (p 99)
Sorafenib (Nexavar) seems to prolong the time it takes for
cancer to start growing again in people who have metastatic
NSCLC that did not respond to chemotherapy.
Colored scanning electron micrograph of the lining of the lung
SUSUMU NISHINAGA/PHOTO RESEARCHERS, INC.
tcontents continued on the following page
The term “small cell” refers to the size and shape of the
cancer cells. Small cell lung cancer begins in the nerve cells or
hormone-producing cells of the lung. It is usually described as
either limited stage (the cancer is located on one side of the
chest) or extensive stage (the cancer has spread to other areas
of the chest or outside the chest). NSCLC starts in the epithelial
cells that line the airways and produce mucus to lubricate and
protect the lungs.
It is important for doctors to disti